What's happened
The FDA approved a 7.2-milligram dose of Novo Nordisk's semaglutide, branded Wegovy HD, for weight management. The higher dose, available in April, aims to improve efficacy for those not reaching their goals with lower doses, with side effects similar to existing treatments.
What's behind the headline?
The approval of Wegovy HD marks a significant step in obesity treatment, targeting a broader patient base. The jump from 2.4 to 7.2 milligrams is substantial, raising concerns about side effects, which include nausea, skin sensations, and serious adverse events. The accelerated FDA review indicates strong industry confidence in the drug's potential, but real-world data will be crucial to assess tolerability. This move underscores the ongoing race among pharmaceutical companies to develop more effective, easier-to-take weight loss medications. The focus on higher doses aims to address the unmet needs of patients who respond suboptimally to current options, potentially reshaping obesity management and expanding market share for Novo Nordisk and competitors like Eli Lilly.
What the papers say
The Independent reports that the FDA approved Wegovy HD after a rapid 54-day review, highlighting its potential to help patients who do not reach their weight loss goals with lower doses. The European regulator approved the higher dose earlier, citing studies where participants lost nearly 19% of their body weight. Dr. Jody Dushay from Harvard Medical School welcomed the approval, noting its benefit for those with suboptimal responses. However, side effects such as nausea and skin sensations remain prevalent, with serious adverse events reported in about 7% of trial participants. The approval signals a competitive push in the weight loss drug market, with Novo Nordisk planning to launch the drug in U.S. pharmacies in April, and pricing details to follow. The New York Times emphasizes the significant weight loss achieved at higher doses, but also notes the large increase from previous doses without intermediate options, raising questions about long-term tolerability and safety.
How we got here
The approval follows earlier European clearance of Wegovy HD and recent FDA approval of an oral semaglutide pill. The higher dose was developed to help patients who do not achieve sufficient weight loss with the standard 2.4-milligram dose, based on clinical trial results showing increased weight loss at the higher dose.
Go deeper
More on these topics
-
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares.
-
The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
-
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.